We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+48.85%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.17%
10 Year Est. Return
+19,957,666.26%
AUM
$634M
AUM Growth
+$33.5M
(+5.6%)
Cap. Flow
-$90.2M
Cap. Flow
% of AUM
-14.22%
Top 10 Holdings %
Top 10 Hldgs %
8.15%
Holding
413
New
130
Increased
19
Reduced
118
Closed
127
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LivePerson
LPSN
|
+$4.19M |
| 2 |
NVTR
Nuvectra Corporation Common Stock
NVTR
|
+$4.14M |
| 3 |
TBCH
Turtle Beach Corp
TBCH
|
+$4.13M |
| 4 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$4.07M |
| 5 |
Tactile Systems Technology
TCMD
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$6.81M |
| 2 |
CUTR
Cutera, Inc.
CUTR
|
+$4.92M |
| 3 |
Vericel Corp
VCEL
|
+$4.77M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$4.75M |
| 5 |
INST
Instructure, Inc.
INST
|
+$4.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.66% |
| 2 | Technology | 24.9% |
| 3 | Consumer Discretionary | 14.4% |
| 4 | Industrials | 10.81% |
| 5 | Financials | 5.13% |
Similar funds
NEPWA
RWM
MCM
HP
OMG
RB
BGC
ICCFIA
EAM Investors's Q2 2018 Portfolio in Review
As of Q2 2018, EAM Investors held 413 positions worth $634M, up 5.6% from $601M the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
EAM Investors withdrew a net $90.2M in Q2 2018, closing 127 positions and reducing 118 holdings. Its most notable exit was Nektar Therapeutics, an estimated $6.81M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 32% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Investors opened a new position in LivePerson worth $4.69M.
- EAM Investors's largest Q2 2018 buy was LivePerson: 14,807 shares worth $4.69M.
- EAM Investors added most to Malibu Boats in Q2 2018, an estimated $3.06M increase.
- EAM Investors's biggest Q2 2018 reduction was Vericel Corp, cutting an estimated $4.77M.
- EAM Investors fully exited Nektar Therapeutics in Q2 2018, selling an estimated $6.81M.
- EAM Investors's ten largest holdings make up 8.1% of its $634M portfolio in Q2 2018.
- EAM Investors opened 130 new positions and closed 127 in Q2 2018.
- EAM Investors's portfolio value rose 5.6% quarter-over-quarter to $634M.
Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.